Regeneron Pharmaceuticals recently reported earnings for Q1 2025 with a revenue drop to $3,029 million compared to the prior year, though net income increased, reflecting robust profitability with ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was ...

Regeneron Pharmaceuticals recently reported earnings for Q1 2025 with a revenue drop to $3,029 million compared to the prior year, though net income increased, reflecting robust profitability with ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was 3% ...

Regeneron anticipates a decline in EYLEA sales ... Recent demand increase of 5% in Q1, though net sales remain flat. - Experienced a 19% global growth and is leading in prescription share.

Q1 2025 Earnings Call Transcript May 27, 2025 BioLineRx Ltd. beats earnings expectations. Reported EPS is $1.39, expectations ...

Vertex Pharmaceuticals Incorporated shares dipped after lower-than-expected Q1 earnings and analysts revising their forecast. DoorDash shares decreased after announcing downbeat first-quarter ...

Biotech company Regeneron (NASDAQ:REGN) in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was 3% below analysts’ consensus estimates.

Overall, the average rating remained a “Moderate Buy,” though with significantly tempered expectations. Regeneron’s Q1 results didn’t help the mood. The company posted earnings of $8.22 per share, ...

Regeneron Pharmaceuticals agreed to purchase 23andMe for $256 million in a bankruptcy court auction, the company said Monday. The move allows 23andMe to continue to provide DNA testing services ...